Ocular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting

Reuters

02/05

<a href="https://laohu8.com/S/OCUL">Ocular Therapeutix</a> to Present Phase 3 SOL-1 Wet <a href="https://laohu8.com/S/AMD">AMD</a> Trial Results at Macula Society Meeting

Ocular Therapeutix Inc. has announced updated timing for the presentation of topline results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD). The results remain masked and are expected to be presented at the 49th Macula Society Annual Meeting scheduled for February 25–28, 2026. The company also completed randomization of 631 subjects in the SOL-R Phase 3 non-inferiority trial in December 2025, with topline results now anticipated in the first quarter of 2027. Ocular Therapeutix plans to submit a new drug application for AXPAXLI in wet AMD based on the SOL-1 52-week data, pending positive results and planned interactions with the U.S. Food and Drug Administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2609583372"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609583372\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609583372?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609583372","market":"fut","top_or_hot":-1,"title":"Ocular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> to Present Phase 3 SOL-1 Wet <a href=\"https://laohu8.com/S/AMD\">AMD</a> Trial Results at Macula Society Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ocular Therapeutix Inc. has announced updated timing for the presentation of topline results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD). The results remain masked and are expected to be presented at the 49th Macula Society Annual Meeting scheduled for February 25–28, 2026. The company also completed randomization of 631 subjects in the SOL-R Phase 3 non-inferiority trial in December 2025, with topline results now anticipated in the first quarter of 2027. Ocular Therapeutix plans to submit a new drug application for AXPAXLI in wet AMD based on the SOL-1 52-week data, pending positive results and planned interactions with the U.S. Food and Drug Administration.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> to Present Phase 3 SOL-1 Wet <a href=\"https://laohu8.com/S/AMD\">AMD</a> Trial Results at Macula Society Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ocular Therapeutix Inc. has announced updated timing for the presentation of topline results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD). The results remain masked and are expected to be presented at the 49th Macula Society Annual Meeting scheduled for February 25–28, 2026. The company also completed randomization of 631 subjects in the SOL-R Phase 3 non-inferiority trial in December 2025, with topline results now anticipated in the first quarter of 2027. Ocular Therapeutix plans to submit a new drug application for AXPAXLI in wet AMD based on the SOL-1 52-week data, pending positive results and planned interactions with the U.S. Food and Drug Administration.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCUL","symbol_name":"Ocular Therapeutix","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL7JHQDK:1","article_id":"2609583372","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609583372","pubTimestamp":1770293159,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ocular Therapeutix Inc. has announced updated timing for the presentation of topline results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI  for the treatment of wet age-related macular degeneration . The results remain masked and are expected to be presented at the 49th Macula Society Annual Meeting scheduled for February 25–28, 2026. The company also completed randomization of 631 subjects in the SOL-R Phase 3 non-inferiority trial in December 2025, with topline results now anticipated in the first quarter of 2027. Ocular Therapeutix plans to submit a new drug application for AXPAXLI in wet AMD based on the SOL-1 52-week data, pending positive results and planned interactions with the U.S. Food and Drug Administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCUL":"Ocular Therapeutix","BK4007":"制药"},"translate_title":"Ocular Therapeutix将在黄斑协会会议上展示3期SOL-1湿性AMD试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUL":0.9},"content_text":"Ocular Therapeutix to Present Phase 3 SOL-1 Wet AMD Trial Results at Macula Society Meeting\n    \n\n        Ocular Therapeutix Inc. has announced updated timing for the presentation of topline results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD). The results remain masked and are expected to be presented at the 49th Macula Society Annual Meeting scheduled for February 25–28, 2026. The company also completed randomization of 631 subjects in the SOL-R Phase 3 non-inferiority trial in December 2025, with topline results now anticipated in the first quarter of 2027. Ocular Therapeutix plans to submit a new drug application for AXPAXLI in wet AMD based on the SOL-1 52-week data, pending positive results and planned interactions with the U.S. Food and Drug Administration.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}